AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy

Description

Discover why reliance on a small subset of “super donors” could introduce risk and ignite ethical considerations for cell and gene therapy companies seeking sustainable growth and scalability.

Learning Objectives:

• Describe how known and unknown inherent differences in human beings and populations can impact starting material
• Describe how access to a large pool of diverse donors is essential for current and future needs
• Discover how the use/overuse of “super donors” involves not only technical, regulatory and medical issues, but also ethical and legal issues
• Discuss strategic solutions for sustainable cell and gene therapy development and growth

Speaker(s):

• Joy Aho, National Marrow Donor Program
• Jason Dehn, MPH, National Marrow Donor Program

Disclosures

• Joy Aho : Nothing to disclose
• Jason Dehn, MPH : Nothing to disclose